v3.25.4
COLLABORATION AND LICENSE AGREEMENTS (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2025
USD ($)
Jul. 31, 2025
USD ($)
performance_obligation
Sep. 30, 2024
USD ($)
Jan. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jan. 31, 2024
May 31, 2023
USD ($)
shares
Oct. 31, 2020
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research and development           $ 338,929 $ 238,254 $ 159,765      
Total revenues           70,849 302 314      
Prepaid expenses and other current assets $ 19,581         19,581 20,877        
ImmunoGen, Inc                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research and development $ 10,000                    
Milestone payments                     $ 48,000
Potential royalty payments                     $ 95,000
Enable Injections                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Milestone payments       $ 45,000              
Potential royalty payments       150,000              
Collaborative arrangement, rights and licenses fee       $ 15,000              
Third Party Collaborator                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Milestone payments                   $ 55,000  
Potential royalty payments                   $ 60,000  
Shares issued in exchange for rights granted (in shares) | shares                   243,902  
Value of shares issued in exchange for rights granted         $ 5,700            
Collaboration                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues           849 302 314      
License                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues           70,000 0 0      
Zenas BioPharma                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research and development           $ 400 1,500        
Zenas BioPharma | Fairmount Funds Management                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Noncontrolling interest ownership (in percent) 5.00%         5.00%          
Paragon Therapeutics                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Research and development           $ 4,500 14,200 $ 12,000      
Collaboration arrangement, future developments milestone payment obligation     $ 16,000                
Collaboration arrangement, maximum milestone payments     40,000                
Future developments milestone payments     3,100                
Commercial milestone payments     $ 17,000                
Prepaid expenses and other current assets             $ 800        
Paragon Therapeutics | Fairmount Funds Management                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Noncontrolling interest ownership (in percent)                 5.00%    
Kissei Pharmaceutical Co., Ltd                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Collaborative arrangement, upfront fee payment   $ 70,000                  
Collaborative arrangement, rights and obligations, milestone payments   $ 315,000                  
Number of performance obligations | performance_obligation   2                  
Kissei Pharmaceutical Co., Ltd | License                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Total revenues           $ 70,000